BioVie Inc.
NASDAQBIVI short interest jumps 35% in one week to 2.31% of float, driven by rising bearish bets amid biotech selloff. Cost to borrow remains elevated at 11.67%, though down 9% from last week. Stock down 11% over same period.
Snapshot as of 19 Oct 2026
BIVI heads into its most critical near-term catalyst — topline Phase 2 data for bezisterim in Parkinson's disease — having gained 12% on the week and 20% over the past month, closing at $1.68. The stock's move is being…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BIVI — free to start on ORTEX.
Sign up for free →Open BIVI on ORTEX